SCS adds to iPS portfolio
Wednesday, 08 October, 2008
Stem Cell Sciences [ASX: STC] has licensed technology developed at Cambridge University used to reprogram adult cells into stem cells.
The agreement relates specifically to patents for technology used to generate induced pluripotent stem (iPS) cells from mammalian cells.
The technology was developed by Professor Austin Smith. Smith, director of the Wellcome Trust Centre for Stem Cell Research.
Smith also serves as chairman of SCS's Scientific Advisory Board.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
